Global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease Market Growth 2024-2030

Global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease Market Growth 2024-2030

Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects the brain, leading to cognitive decline and memory loss. It is the most common cause of dementia, a syndrome characterized by a decline in cognitive function that interferes with daily life. Alzheimer's disease is named after Dr. Alois Alzheimer, who first identified the condition in 1906.

Currently, there is not significant leading product on the market, and the competition landscape for AD diagnostic reagents is relatively good. In the future, with the approval of more accurate mass spectrometry and other kits, the application of combined detection methods, and the approval of more AD treatment drugs, the AD diagnostic industry has huge development potential, and the market space may further expand.

The cerebrospinal fluid (CSF) biomarkers, that were first developed by Fujirebio more than 25 years ago, have evolved over time from research biomarkers into specialized diagnostic testing tools, and from manual usage by early adopters to a widespread implementation in fully automated routine testing today.

Diagnosis for Alzheimer’s disease using CSF samples allows the detection of four proteins: two forms of amyloid (Aβ1-42 and Aβ1-40) proteins and two forms of Tau (Total Tau and phospho-Tau) proteins. If a patient has Alzheimer’s disease, then these proteins will be present in abnormally low (Aβ1-42 and Aβ1-42/Aβ1-40 ratio) and high (Total Tau and phospho-Tau) levels. The Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio will even be low long before the symptoms of the disease start to show.

In the clinical community today, there are high hopes for the use of blood-based testing for even simpler and potentially more widespread testing for Alzheimer’s disease in clinical routine.

The global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market size is projected to grow from US$ 43.5 million in 2024 to US$ 126 million in 2030; it is expected to grow at a CAGR of 19.4% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease Industry Forecast” looks at past sales and reviews total world Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease sales in 2023, providing a comprehensive analysis by region and market sector of projected Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease sales for 2024 through 2030. With Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease industry.

This Insight Report provides a comprehensive analysis of the global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease.

Rising Prevalence of Alzheimer's Disease: The increasing global prevalence of Alzheimer's disease is a significant driver for the development of early diagnosis kits. As the aging population grows, the demand for reliable diagnostic tools for early detection becomes more critical.

Focus on Early Intervention and Treatment: With the recognition that early intervention and treatment may have a more significant impact on disease progression, there is a growing emphasis on the development of tools that enable early diagnosis. This shift in therapeutic strategies encourages investment in early detection technologies.

Technological Innovations in Diagnostics: Advances in diagnostic technologies, including imaging techniques, molecular diagnostics, and blood-based assays, contribute to the development of more sophisticated and precise early diagnosis kits. These innovations enhance the sensitivity and specificity of diagnostic tools.

This report presents a comprehensive overview, market shares, and growth opportunities of Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Magnetic Particle Chemiluminescence Methods
Enzyme-linked Immunoassay Methods
Chemiluminescence Immunoassay Methods
Dry Fluorescence Immunochromatography Methods
Others

Segmentation by Application:
Clinical Diagnosis
Research

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Fujirebio
Quanterix
People Bio
Easund Bio-tech and Pharmakea
MagQu
Solgent
Sysmex
Immuno-Biological Laboratories
Shenzhen Anqun Bioengineering
Amoneta Diagnostics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market?

What factors are driving Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market opportunities vary by end market size?

How does Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease break out by Type, by Application?



Please note: The report will take approximately 2 business days to prepare and deliver.